Detect, Monitor, and Enable Effective Treatment for Metabolic Disease
Hepta is an AI-native liquid biopsy company focused on non-invasive diagnostics for metabolic liver disease. Its platform interprets epigenetic patterns in cell-free DNA from a standard blood draw to reveal liver biology, enabling earlier detection and treatment of MASH (metabolic dysfunction-associated steatohepatitis). Founded by former Illumina, GRAIL, and Google leaders, Hepta is headquartered in San Francisco.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account